A study published in scientific journal The Lancet showed that the Russian-made coronavirus vaccine Sputnik V has 91.6-percent efficacy against mild cases of Covid-19. The news comes after Russia’s Gamaleya Institute — the manufacturer of Sputnik V — faced severe international backlash due to a lack of transparency in clinical trials.
The vaccine is already being used in Latin American countries such as Argentina and Bolivia.
The Brazilian states of Paraná and Bahia have signed contracts with the Russian Direct Investment Fund in order to acquire Sputnik V shots, but regulator Anvisa denied a request for the vaccine’s emergency approval, as late-stage clinical trials are not being held in Brazil.
On Tuesday afternoon, Anvisa said that the Sputnik V results were “good news,” but that the regulator would require “access to the complete data from clinical trials” before being able to approve the vaccine.
In 2000, Formula 1 great Michael Schumacher had just racked up his 41st race win,…
Overall, the worldwide economic outlook has improved according to the Organization for Economic Co-operation and…
“This is f***ing corruption, it has to change,” protested an irate John Textor, owner of…
Eduardo Leite, governor of the southern Brazilian state of Rio Grande do Sul, on Wednesday…
Moody’s is the latest rating agency to improve its assessment of Brazil, bumping up the…
Other finalists include the Harvard Business Review, Fortune, Condé Nast, and the NFL